Login to Your Account



VC funding in hand, Cstone files China IND for PD-L1 antibody

By Shannon Ellis
Staff Writer

Friday, October 21, 2016

SHANGHAI – Starting out with a bang, newly formed biopharma Cstone Pharmaceuticals Co. Ltd. has filed an investigative new drug application with the Jiangsu FDA for its recombinant anti-PD-L1 monoclonal antibody (WBP3155).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription